Stock Price Quote

DR. LAL PATHLABS LTD.

NSE : LALPATHLABBSE : 539524ISIN CODE : INE600L01024Industry : Hospital & Healthcare ServicesHouse : Arvind Lal
BSE2620.10-4.8 (-0.18 %)
PREV CLOSE ( ) 2624.90
OPEN PRICE ( ) 2623.50
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 921
TODAY'S LOW / HIGH ( )2585.75 2640.75
52 WK LOW / HIGH ( )1943.2 3645
NSE2620.30-3.2 (-0.12 %)
PREV CLOSE( ) 2623.50
OPEN PRICE ( ) 2623.50
BID PRICE (QTY) 2620.30 (1)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 100927
TODAY'S LOW / HIGH( ) 2587.05 2662.30
52 WK LOW / HIGH ( )1943.7 3653.95
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 14-02 1995
Management Info
Arvind Lal - Chairman - Managing Director
Registered Office

Address Block E,Sector 18,Rohini,
New Delhi,
Delhi-110085

Phone 011-30258600

Email lalpathlabs@lalpathlabs.com

Website www.lalpathlabs.com

Registrars Details
MUFG Intime India Pvt Ltd.
Noble Heights, 1st Floor, Plot NH 2,C-1 Block LSC, Near Savitri Market,Janakpuri,New Delhi
Listing : BSE, NSE

NEWS

07Feb Dr. Lal PathLabs informs about postal
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Re..
24Jan Dr. Lal PathLabs informs about confere
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosur..
18Dec Dr. Lal PathLabs informs about allotme
Dr. Lal PathLabs has informed that the Board of Directors through Circul..
26Nov Dr. Lal PathLabs informs about analyst
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Re..
16Oct Dr. Lal PathLabs informs about board m
Dr. Lal PathLabs has informed that a meeting of the Board of Directors i..

Financials

in Millions
QTR Dec 24 ANNUAL 24
Net Profit11453844
Gross Profit 1512 5160
Operating Profit 17496193
Net Sales 528119668

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Max Healthcare Inst (BSE)
peergroup  1004.85 (0.40%)
M.Cap ( in Cr)97685.69
Asarfi Hospital Ltd. (BSE)
peergroup  93.63 (1.99%)
M.Cap ( in Cr)184.24
Gian Life Care (BSE)
peergroup  15.50 (2.38%)
M.Cap ( in Cr)16.03
KMC Speciality Hosp (BSE)
peergroup  69.36 (0.23%)
M.Cap ( in Cr)1131.16
Narayana Hrudayalay (BSE)
peergroup  1329.40 (0.01%)
M.Cap ( in Cr)27167.73

Shareholding Pattern

NON-INSTITUTION 6.11%
PROMOTERS 53.91%
FI/BANKS/INSURANCE 2.53%
MUTUAL FUNDS/UTI 10.25%
GOVERNMENT 0%
FII 0%

About Dr. Lal Pathlabs Ltd.

Dr. Lal Pathlabs Ltd. was incorporated in the year 1995. Its today's share price is 2620.1. Its current market capitalisation stands at Rs 21900.82 Cr. In the latest quarter, company has reported Gross Sales of Rs. 19667.58 Cr and Total Income of Rs.20268.64 Cr. The company's management includes Gurinder Singh Kalra, Somya Satsangi, Rajit Mehta, Rohit Bhasin, Rahul Sharma, Arun Duggal, Om Prakash Manchanda, Archana Lal Erdmann, Vandana Lal, Arvind Lal, Vinay Gujral.

It is listed on the BSE with a BSE Code of 539524 , NSE with an NSE Symbol of LALPATHLAB and ISIN of INE600L01024. It's Registered office is at Block E,Sector 18,RohiniNew Delhi-110085, Delhi. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells LLP, SR Batliboi & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.